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Abstract
In the last decade, the widespread use of massively parallel sequencing has considerably 
boosted the number of novel gene discoveries in monogenic skeletal diseases with 
short stature. Defects in genes playing a role in the maintenance and function of the 
growth plate, the site of longitudinal bone growth, are a well-known cause of skeletal 
diseases with short stature. However, several genes involved in extracellular matrix 
composition or maintenance as well as genes partaking in various biological processes 
have also been characterized. This review aims to describe the latest genetic findings in 
spondyloepiphyseal dysplasias, spondyloepimetaphyseal dysplasias, and some monogenic 
forms of isolated short stature. Some examples of novel genetic mechanisms leading to 
skeletal conditions with short stature will be described. Strategies on how to successfully 
characterize novel skeletal phenotypes with short stature and genetic approaches to detect 
and validate novel gene-disease correlations will be discussed in detail. In summary, we 
review the latest gene discoveries underlying skeletal diseases with short stature and 
emphasize the importance of characterizing novel molecular mechanisms for genetic 
counseling, for an optimal management of the disease, and for therapeutic innovations.
Introduction
Genetic skeletal diseases, often called skeletal dysplasias, 
are a heterogeneous group of heritable conditions with 
generalized bone and cartilage impairment caused 
by pathogenic variants in genes primarily affecting 
skeletogenesis and/or bone homeostasis (1, 2). Although 
the overall incidence of genetic skeletal diseases is around 
one in 5000 births (3), some conditions are extremely rare 
and can only be found in a handful of families worldwide. 
In the last decade, the widespread use of massively 
parallel sequencing (MPS) has boosted the diagnostic rate 
of rare skeletal diseases and has led to the identification 
of several novel disease loci. According to the latest 
Nosology of Skeletal Disorders published in 2019, in 
total 461 skeletal diseases have been characterized so far. 
These diseases have been classified into 42 groups based 
on a combination of radiological findings, clinical 
features, and underlying molecular mechanisms (2). 
Genetic skeletal diseases are characterized by a broad 
phenotypic heterogeneity. The clinical manifestations can 
vary greatly among patients with the same gene defect and 
significantly even among those harboring the exact same 
pathogenic variant. This broad phenotypic and genetic 
heterogeneity brings challenges in establishing efficient 
treatments. Presently, a pharmacological treatment is only 
available for a limited number of bone disorders, including 
various genetic forms of osteoporosis, FGF23-related 
hypophosphatemia (MIM 193100), hypophosphatasia 
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Although genetic skeletal diseases most often feature 
short and disproportionate stature, sometimes normal 
or even tall stature, like in overgrowth syndromes, can 
be noticed. Moreover, short stature is sometimes part of 
a broader phenotypic spectrum that also includes other 
skeletal impairments, such as short extremities, skeletal 
deformities, high or low bone mineral density as well 
as extra-skeletal features, including impaired vision or 
hearing. The scope of this review is to describe the latest 
genetic discoveries underlying some severe skeletal 
diseases characterized by short stature.
Skeletal diseases with reduced linear growth
Longitudinal linear bone growth is determined by 
endochondral ossification, which is mediated by the 
growth plate, a complex cartilaginous structure located 
between the metaphysis and the epiphysis of the long 
bones (Fig. 1). From the epiphyseal end the growth 
plate can be subdivided into three different zones, each 
of which is composed of chondrocytes characterized by 
different size, shape, orientation, proliferative capacity, 
and function: (1) resting zone, (2) proliferative zone 
and (3) hypertrophic zone (7). The resting zone is a 
source of stem-like progenitor cells restoring the pool of 
proliferative chondrocytes (8). In the proliferative zone, 
the flattened chondrocytes divide longitudinally at a 
high rate and synthetize a large amount of ECM. Finally, 
in the hypertrophic zone chondrocytes stop dividing, 
become large in size, and start producing factors that 
trigger mineralization and the invasion of blood vessels, 
thus promoting chondrocyte apoptosis (9). Consequently, 
osteoblasts invade the hypertrophic zone and bone 
formation takes place. At the end of puberty, when linear 
growth no longer occurs, the growth plate fuses with the 
epiphysis.
Pathogenic variants in several genes encoding factors 
involved in chondrocyte proliferation and differentiation 
as well as defects in ECM components and cell-matrix 
interactions are known to be responsible for different 
monogenic skeletal conditions often accompanied by short 
stature (Fig. 1). Moreover, in some conditions growth plate 
defect can be secondary to abnormal bone metabolism 
and/or mineralization, such as in hypophosphatemic 
rickets (MIM 307800), in which hypophosphatemia leads 
to impaired chondrocyte apoptosis (10).
As mentioned previously, usually disproportionate 
short stature is not an isolated finding, but it is part of a 
wider spectrum of clinical features. From 2015 to 2019, 
pathogenic variants in 45 novel genes have been linked 
to skeletal diseases (2, 11). Among these, 15 novel gene 
defects, which have also been included in the Online 
Mendelian Inheritance in Man (OMIM) database, have 
been linked to either spondylometaphyseal dysplasia 
(SMD) or spondyloepimetaphyseal dysplasia (SEMD), 
two diseases that are mainly characterized by severe short 
stature and skeletal impairments affecting the spine, 
metaphyses and epiphyses (only SEMD) (Table 1) (2). 
In addition, pathogenic variants in the gene encoding 
the ribosomal protein eL13 (RPL13) have been recently 
linked to a novel form of SEMD (Table 1) (12, 13). These 
newly characterized conditions are caused by pathogenic 
variants in genes involved in several different biological 
and molecular processes (Fig. 2). Below, some examples of 
these conditions will be described in more detail.
Defects in fibronectin-1 cause SMD-corner 
fracture type
Fibronectin-1 (FN) is a dimeric glycoprotein that is 
abundant in several tissues and can be found either in 
a soluble form, like in the plasma, or as an insoluble 
multimeric fibrillar component of the ECM (14). 
FN is important for mesenchymal stem cell (MSC) 
differentiation and for deposition of collagen type I in 
the ECM (15, 16). Monoallelic pathogenic mutations in 
the fibronectin-1 gene (FN1) were first identified in 2017 
in patients with a subtype of SMD, namely SMD with 
corner fractures (SMD-CF) (MIM 1842559) (17). Corner 
fractures are not considered as real fractures but they 
are key radiological findings appearing as lucent areas 
in the proximal metaphyses (growth plate) of tubular 
bones (18). SMD-CF was first described by Sutcliffe in 
1966 and it was recognized as a separate entity in 1990 
(19). Since then, approximately 30 families have been 
reported and while pathogenic variants in COL2A1 were 
identified in some subjects with SMD-CF, most of the 
patients lacked a genetic diagnosis for several decades (17, 
20, 21). Nowadays, 11 different disease-causing missense 
variants and a single amino acid deletion in FN1 have 
been reported in 13 families with SMD-CF (17, 20, 21). 
In addition to corner fractures, patients typically feature 
short stature, developmental coxa vara, scoliosis, and 
abnormal ossification at the growth plate and secondary 
ossification sites. 
FN is a dimer constituted by three types of modules, 
domains types I–III, which bind other components of the 
ECM, such as collagen, integrins and glycosaminoglycans 
as well as signaling and cell adhesion molecules (14, 22). 
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Interestingly, the majority of the pathogenic variants 
that have so far been linked to SMD-CF locate within 
the fibronectin type-I domains. In particular, nine out 
of the 11 reported variants associated with SMD-CF 
affect cysteine residues partaking in disulfide bonds, 
which maintain the highly organized structure of FN. 
Pathogenic variants in FN1 impair the secretion of FN 
into the ECM in patient-derived fibroblasts as well as 
in HEK293 cells transfected with plasmid expressing 
mutant FN (17, 20). Surprisingly, pathogenic variants 
in FN domain type III cause another disease, named 
Glomerulopathy with fibronectin deposits 2 (phenotype 
MIM 601894). Renal dysfunction has not been reported 
in any patient with SMD-CF thus suggesting that the 
location of the pathogenic variant determines the 
development of either one or the other disease.
Figure 1
Structure of a long bone with major focus on the growth plate and the key genes regulating longitudinal bone growth. On the left, structure of a long 
bone. Pink panel: schematic representation of the chondrocytes within the three different zones of the growth plate. On the right, some key genes 
regulating longitudinal bone growth and list of monogenic skeletal conditions caused by pathogenic mutations in each of these genes (96, 97, 98). ACAN, 
aggrecan; BMP1, bone morphogenetic protein 1; COL2A1, collagen type II alpha 1 chain; COL10A1, collagen type X alpha 1 chain; FGFR1-3, fibroblast growth 
factor receptor 1-3; GHR, growth hormone receptor; IGF1, insulin-like growth factor 1; IGF1R, insulin-like growth factor 1 receptor; IHH, Indian hedgehog 
signaling molecule; MEF2C, myocyte enhancer factor 2C; MMP9/13, matrix metallopeptidase 9/13; NOTCH1, Notch receptor 1; OSX, Sp7 transcription 
factor; PTH1R, parathyroid hormone 1 receptor 2; PTHLH, parathyroid hormone-like hormone; RUNX2, Runt-related transcription factor 2; SOX9/5, SRY-Box 
transcription factor 9/5; MIM, phenotype OMIM number.




https://ec.bioscientifica.com © 2021 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 08/11/2021 09:10:50AM
via free access





Table 1 Novel genetic defects underlying SMD and SEMD.




AIFM1 Apoptosis inducing 
factor mitochondria 
associated 1
Mitochondrial protein involved in 
oxidative phosphorylation and 
redox control in healthy cells
SEMD XLR 300232 Mierzewska et al. 2017 (99)
BGN Biglycan Structural component of articular 
cartilage. It participates in the 
assembly of the chondrocyte 
extracellular matrix and it also plays 
a role in cell signaling 
SEMD XLR 300106 Cho et al. 2016 (100)
COL27A1 Collagen type XXVII 
alpha 1 chain
Plays a role during the calcification of 
cartilage and in the transition of 
cartilage to bone
SEMD AR 615155 Gonzaga et al. 2015 (101)
EXTL3 Exostosin-like 
glycosyltransferase 3 
Glycosyltransferase that catalyzes the 
transfer of N-acetylglucosamine to 
glycosaminoglycan chains. This 
reaction is important in heparin and 
heparan sulfate synthesis
SEMD AR 617425 Volpi et al. 2017 (102)
FN1 Fibronectin 1 Glycoprotein binding cell surfaces 
and various compounds including 
collagen, fibrin, heparin, DNA,  
and actin
SMD AD 184255 Lee et al. 2017 (17)
HSPA9 Heat shock protein 
family A (Hsp70) 
member 9
Chaperone in the mitochondria, 
cytoplasm, and centrosome






isoleucine-tRNA synthetase that 
catalyzes the attachment of an 
isoleucine residue to a cognate 
mt-tRNA
SEMD AR 616007 Schwartzentruber et al. 
2014 (104)
LTBP3 Latent transforming 
growth factor beta 
binding protein 3
Involved in TGF-beta signaling 
pathway
SEMD AR 601216 Huckert et al. 2015 (105)
NANS N-acetylneuraminate 
synthase
Enzyme that functions in the 
biosynthetic pathways of sialic acids




Enzyme that catalyzes the conversion 
of phosphatidylserine to 
phosphatidylethanolamine in the 
inner mitochondrial membrane
SEMD AR NA Girisha et al. 2019 (107)
RPL13 Ribosomal protein eL13 Component of the large ribosomal 
subunit 60S
SEMD AD 618728 La Caignec et al. 2019 (12)
RSPRY1 Ring finger and SPRY 
domain containing 1
Glycoprotein with unknown function SEMD AR 616723 Faden et al. 2015 (108)
SGMS2 Sphingomyelin  
synthase 2
A major component of cell and Golgi 
membranes involved in the 
synthesis of sphingomyelin
SMD AD 126550 Pekkinen et al. 2019 (13)
TONSL Tonsoku like, DNA 
repair protein
Involved in DNA replication SEMD AR 271510 Burrage et al. 2019 (109)
TRIP11 Thyroid hormone 
receptor interactor 11 
Predicted to play a role in the 
assembly and maintenance of the 
Golgi ribbon structure around the 
centrosome
SMD AR 184260 Wehrle et al. 2019 (110)
UFSP2 UFM1 specific  
peptidase 2
Involved in protein ubiquitination SEMD AD 617974; 
142669
Di Rocco et al. 2018 (111)
AD, autosomal dominant; AR, autosomal recessive; IP, inheritance pattern; NA, not available; SMD, spondylometaphyseal dysplasia; SEMD, 
spondyloepimetaphyseal dysplasia; XLR, X-linked recessive.
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Although additional experiments are required to 
investigate the consequences of pathogenic variants in 
FN1 on the bone ECM, the critical role of FN in skeletal 
development and tissue maintenance is confirmed by the 
lethality of mice lacking FN (23).
Defects in sphingomyelin synthase 2 cause SMD
Sphingomyelin is a sphingolipid of the plasma membrane 
and the Golgi membranes. Monoallelic pathogenic 
variants in the gene encoding sphingomyelin synthase 
2 (SGMS2), an enzyme that catalyzes the synthesis of 
sphingomyelin, have recently been identified in patients 
affected by a rare form of genetic osteoporosis, named 
Calvarial doughnut lesions with bone fragility with or 
without SMD (MIM 126550) (24). Thus far, only three 
different SGMS2 pathogenic variants in eight unrelated 
families have been described in the literature (24, 25). 
While some patients only have early-onset osteoporosis, 
the most severely affected patients feature severe short 
stature, neonatal fractures, and SMD. The variable severity 
of the disease is related to the type of pathogenic variant: 
subjects harboring the nonsense variant c.148C>T 
(p.Arg50*) are either healthy (25) or more mildly affected 
than patients with the missense changes c.185T>G 
(p.Ile62Ser) or c.191T>G (p.Met64Arg) (24). The absence 
of a bone phenotype in some patients harboring the 
nonsense variant suggests incomplete penetrance. The 
p.Arg50* change generates a truncated protein that lacks 
the whole membrane-spanning core domain and leads to 
a catalytically inactive enzyme (24). On the other hand, in 
cell and yeast models, the two missense variants produce 
a catalytically active enzyme that accumulates in the 
endoplasmic reticulum and synthesizes sphingomyelin at 
a remarkably higher rate than the wildtype enzyme. Since 
SMS2 is a homodimer the missense pathogenic variants 
might lead to a dominant-negative effect induced by the 
mutated SMS2 forming a heterodimer with the wildtype 
enzyme. Patient-derived bone biopsies reveal significant 
tissue-level pathology, thin cortical bone, and disturbed 
bone mineralization (24, 25). Pathogenic variants in 
two genes encoding two other enzymes involved in 
sphingomyelin metabolism, phosphatidylserine synthase 
1 (PTDSS1) and choline-phosphate cytidylyltransferase 
A (PCYT1A), cause two other types of skeletal dysplasias, 
named Lenz-Majewski syndrome (MIM 151050) (26) and 
spondylometaphyseal dysplasia with cone-rod dystrophy 
(MIM 608940) (27).
Defects in ribosomal protein eL13 cause SEMD
In some cases, short stature and skeletal abnormalities 
can arise from pathogenic mutations in genes encoding 
ribosomal proteins (RPs), transcribing ribosomal RNAs 
(rRNAs) or required for ribosome biosynthesis (28). 
Ribosomes are vital organelles of the cells that are 
responsible for synthetizing proteins. Eukaryotic ribosomes 
(80S) are composed of two subunits: the large 60S subunit 
and the small 40S subunit. Human ribosomes are mainly 
located in the cytoplasm (either bound to the endoplasmic 
reticulum or floating in the aqueous part) and are formed 
by a complex of around 80 RPs and four rRNAs (29, 30). 
Recently, we and others identified inherited or de novo 
pathogenic variants in the gene encoding the ribosomal 
Figure 2
Function of the 16 genes recently linked to SMD 
and SEMD. Most of the genes recently reported as 
causing SMD and SEMD play a role in the ECM 
(5/16), in the mitochondria (3/16) and in the Golgi 
apparatus (2/15). Each of the remaining genes is 
involved in a different biological mechanism.
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protein eL13 (RPL13) in altogether nine index patients 
with skeletal dysplasia without extra-skeletal features 
(12, 13, 31). The phenotype of the so far reported patients 
with pathogenic RPL13 variants varies greatly and it ranges 
from normal stature with multiple epiphyseal dysplasia in 
one patient (31) to disproportionate short stature, growth 
deficiency, broad metaphyses, and delayed ossification 
of the epiphyses in the majority of the other patients. 
Interestingly, in two families variable clinical expressivity 
and incomplete penetrance of the disease have been 
identified (13). Surprisingly, in one family the index 
patient died during early childhood while his mother is 
healthy, despite harboring the same RPL13 mutation as 
her child (13). Polysome profiling, carried out in both 
patient-derived lymphoblasts and dermal fibroblasts, 
shows a reduced 80S peak, thus suggesting a change in 
translation efficiency (12, 13). Moreover, a zebrafish 
model harboring a frameshift deletion within rpl13 partly 
recapitulates the human phenotype by featuring cartilage 
deformities during early stages of development (13). 
Although the molecular mechanisms underlying skeletal 
dysplasia RPL13-type are yet unknown, tissue specificity 
with skeletal involvement and incomplete penetrance 
of the disease have been found in other conditions 
caused by ribosomal dysfunction, collectively named 
ribosomopathies (28, 32). Tissue specificity suggests that 
ribosomes could be involved in other mechanisms beside 
translation (33) and RPL13 might potentially play a role 
in skeletogenesis. 
Concerning the presence of short stature and 
skeletal abnormalities due to defects in ribosomal 
components, other congenital conditions with these 
clinical features have been described previously, including 
CHH, Diamond-Blackfan anemia 1 (MIM 105650), and 
Shwachman-Diamond syndrome (MIM 260400) (34). 
Moreover, common findings among ribosomopathies are 
bone marrow failure and anemia. Although the patients 
that have so far been reported as being affected by skeletal 
dysplasia RPL13-type do not feature hematological 
impairments, bone marrow dysfunction could lead 
to defective mesenchymal stem cell production, 
consequently affecting chondrogenic/osteogenic 
differentiation. Moreover, patients with ribosomopathies 
often have increased propensity to develop cancer (35, 
36). Since only nine families with skeletal dysplasia due 
to RPL13 variants have been described so far, it is not 
possible to estimate the cancer risk for this type of skeletal 
dysplasia. Certainly, more patients need to be identified 
and characterized to better delineate the clinical and 
genetic scenario of skeletal dysplasia RPL13-type and 
additional functional work, possibly using chondrogenic/
osteogenic cell lines and in vivo models, is required to fully 
explore the pathogenesis of the disease.
Mildest forms of skeletal dysplasia in patients 
diagnosed with idiopathic short stature
Idiopathic short stature (ISS) is defined as stature more 
than 2 s.d. below the mean for age and sex, when no cause 
for the short stature has been identified despite standard 
clinical and laboratory evaluation (37, 38). For diagnosis 
of ISS, systemic or endocrine diseases, dysmorphic 
syndromes, small birth size (small for gestational age, 
SGA), and skeletal dysplasias should be excluded (38). 
Height is a polygenic trait and several hits associated to 
height variation have been identified by genome-wide 
association studies so far (39, 40). However, monogenic 
forms of short stature have also been identified. In cohorts 
of ISS children, some children have pathogenic variants 
in genes that are associated with skeletal dysplasias and 
ISS phenotype, thus represents the mildest end of the 
spectrum of these disorders.
One well-known example is short stature homeobox 
(SHOX) haploinsufficiency, which causes short stature 
in 2–15% of children previously diagnosed with ISS 
(MIM 300582) (41). In addition to isolated short 
stature, heterozygous SHOX pathogenic variants cause 
Leri-Weill dyschondrosteosis (MIM 127300), a skeletal 
dysplasia characterized by disproportionate short stature, 
mesomelic limb shortening, and the Madelung deformity 
(42). On the other hand, biallelic pathogenic variants in 
SHOX cause the more severe Langer mesomelic dysplasia 
(MIM 249700) (43). The clinical severity of SHOX 
pathogenic variants varies even within family members 
carrying the same variant and damaging mutations of 
the gene encoding the retinoic acid catabolizing enzyme 
(CYP26C1) have been reported to act as genetic modifiers 
of SHOX deficiency (44). Recently, it was reported that 
CYP26C1 damaging mutations without SHOX deficiency 
can also lead to short stature (45).
Pathogenic variants in natriuretic peptide receptor 2 
gene (NPR2) also cause a large variability in phenotype, 
ranging from acromesomelic dysplasia (MIM 602875), 
caused by biallelic mutations, to isolated short stature 
(MIM 616555). Family members who were mutation 
carriers were found to have significantly lower height 
than non-carrier family members and the general 
population, suggesting that heterozygous variants in 
NPR2 are associated with short stature (46). Subsequent 
studies in ISS cohorts have found heterozygous NPR2 
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variants in 2–6% of the patients (47, 48, 49). Variable 
phenotype was observed, with cases of both proportional 
and disproportional short stature. NPR2 is the principal 
receptor of natriuretic peptide C, encoded by the 
natriuretic peptide precursor C (NPPC). Heterozygous 
NPPC pathogenic variants have been identified as a cause 
of short stature and small hands phenotype in 0.6% of 
patients with short stature (50). 
Pathogenic variants in the fibroblast-growth factor 
receptor 3 (FGFR3) are responsible for a wide range of 
clinical severity, from lethal thanatophoric dysplasia 
types I and II (MIM 187600-187601) to nonlethal 
achondroplasia (MIM 100800) and hypochondroplasia 
(MIM 146000) (51). In 2015, a FGFR3 variant was 
determined as a cause of proportionate short stature in 
one family (52), further widening the clinical spectrum. 
Interestingly, an analog of C-type natriuretic peptide, 
which promotes bone growth by inhibiting fibroblast-
growth factor-mediated mitogen activated protein kinase 
(MAPK) activation, is presently used in phase III trials to 
treat achondroplasia (6).
Aggrecan (ACAN) is a proteoglycan in the extracellular 
matrix and its major function is to resist compression 
in cartilage. Homozygous or compound heterozygous 
pathogenic variants in ACAN cause SEMD aggrecan type 
(MIM 612813), while heterozygous pathogenic variants 
can cause either spondyloepiphyseal dysplasia Kimberley 
type (MIM 608361) or short stature with advanced bone 
age (MIM 165800) (2). Many patients with short stature 
and advanced bone age caused by pathogenic variants in 
ACAN develop early-onset osteoarthritis and degenerative 
disc disease (53). Midface hypoplasia, joint problems, and 
broad great toes have also been reported (54). Recently, 
subjects with ACAN haploinsufficiency were reported 
to have an elevated mean arm span to height ratio in 
childhood and adolescence, and a slightly elevated ratio 
until age 50 (53, 55).
Indian hedgehog signaling molecule (IHH) is known 
to cause acrocapitofemoral dysplasia (MIM 607778), 
brachydactyly type A1 (MIM 112500), syndactyly (Lueken 
type) and syndactyly with craniosynostosis (Fig. 1) (2). 
Additionally, heterozygous pathogenic IHH variants 
causing short stature have been identified in a cohort 
of patients with growth disorders (56). Short stature 
was mildly disproportionate in most cases and many 
had shortening of the middle phalanx of second and/or 
fifth finger. Some of the patients were born small for 
gestational age (SGA). Recently, heterozygous pathogenic 
IHH variants were identified in another cohort with short 
stature and/or brachydactyly, including the first patient 
with a complete deletion of IHH, who presented with 
both short stature and brachydactyly (57).
Novel molecular mechanisms underlying 
skeletal diseases
For a long time, it has been thought that the non-coding 
genome (approximately 98% of the whole genome), 
also named junk DNA, does not play any vital function. 
However, this concept has been disproved by the 
discovery of skeletal diseases caused by variants in the 
non-coding regulatory genome and two examples are 
discussed here. 
Aberrant microRNA (miRNA) expression and 
processing, miRNA deletions as well as point mutations in 
miRNA have been associated with congenital conditions 
(58). In 2019, the first skeletal dysplasia caused by 
gain-of-function pathogenic variants in a miRNA, 
miRNA-140, were characterized by Grigelioniene   et  al. 
(59). The three patients from two families affected 
by this disease, named spondyloepiphyseal dysplasia 
Nishimura type (MIM 618618), mainly feature dwarfism, 
short limbs, and small hands and feet. All affected 
subjects had the same heterozygous missense variant, 
MIR140:NR_029681.1:n.24A>G, in the seed sequence of 
miRNA-140, which is highly expressed in chondrocytes 
and it was found to be associated with a chondrocyte-
specific super-enhancer both in humans and mice (59). 
Mice lacking this miRNA are short and have craniofacial 
deformities (60). Heterozygous and homozygous knock-in 
mice harboring the same pathogenic variant as detected 
in the patients showed a more severe phenotype, 
including also delayed secondary ossification of tubular 
and carpal bones, delayed cartilage development in the 
larynx, trachea, anterior ribs, and decreased expression of 
Col10a1 (59). 
In recent years, the discovery of topological associated 
domains (TADs), megabase-scale 3D rearrangements of 
the chromatin, has demonstrated that regulatory regions 
might be located far away (in terms of linear DNA sequence) 
from the gene they regulate (61). Acropectorovertebral 
dysplasia (MIM 102510), characterized by carpal and tarsal 
synostoses, syndactyly, hypodactyly and polydactyly of 
feet as well as spina bifida occulta arises from structural 
variants (SVs) disrupting a TAD domain spanning the 
genes WNT6, IHH, EPHA4, and PAX3 (62). This TAD 
disruption is likely to rewire gene-enhancer interactions, 
leading to abnormal gene expression. Disruption of other 
TAD domains might then be the cause of other skeletal 
diseases with unknown genetic basis.
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How to identify novel phenotypes
Novel skeletal disorders and their genetic etiology can be 
studied by combining careful phenotyping with selected 
genetic strategies. Assessment includes detailed family 
history and information about possible consanguinity, 
in order to determine the possible inheritance pattern. As 
skeletal dysplasias may present in different family members 
with a varying degree of severity, a clinical evaluation of 
family members may be necessary to determine whether 
they might have a mild form of the same disease. 
In a patient with short stature, accurate and 
multiple growth chart measurements, including SDS for 
height, weight, and head circumference are essential 
for assessing growth. It should be determined whether 
the patient was born with short stature and whether 
macrocephaly is present. Disproportionate short stature 
is typical in skeletal dysplasia and it can be assessed by 
measuring arm span, sitting height, and sitting height/
height ratio. Alternatively, the upper/lower body segment 
ratio can be calculated and compared to references (38). 
Disproportionate short stature affecting the limbs can be 
either rhizomelic, mesomelic or acromelic depending on 
whether proximal (humerus and femur), middle (radius, 
ulna, tibia, or fibula), or distal (hand and foot) segments 
are shortened (63). Spinal involvement may be difficult 
to evaluate clinically and often requires radiographic 
assessment.
Evaluation of facial dysmorphic features may include 
evaluation of the fontanels, nasal bridge, midface, 
philtrum, mandible, palate, and ears (1). One should 
also assess upper and lower limb lengths and possible 
asymmetry, carrying angle of the elbow, and any anomalies 
in the digits (oligo-, poly-, brachy- or syndactyly). Frontal 
bossing, cleft palate, dental defects, clavicle aplasia or 
hypoplasia, scoliosis, joint hyperlaxity/contractures/
dislocations, genu varum or valgum, fractures, and 
abnormalities in nails, hair, and skin should be examined. 
Skeletal dysplasias may also be associated with various 
extra-skeletal manifestations, such as problems in hearing, 
vision, renal or respiratory system, heart defects, genital 
abnormalities, immune deficiency, anemia, and intestinal 
problems such as Hirschprung disease (1, 63, 64, 65). 
Further evaluation of these systems may be needed. 
Skeletal survey is an essential tool in assessing skeletal 
dysplasias. A skeletal survey may include radiographs 
of the skull (posteroanterior and lateral), spine 
(anteroposterior and lateral), thorax (anteroposterior), 
pelvis (anteroposterior), upper limb (anteroposterior), 
left hand and wrist (posteroanterior) and lower limb 
(anteroposterior) (38). Based on localization of radiological 
findings, the dysplasias can be characterized as spondylo, 
epiphyseal, metaphyseal or diaphyseal dysplasia, or a 
combination of these. 
Genetic approaches to variant and 
gene discoveries
In addition to an in-depth clinical investigation, choosing 
the correct genetic approach to investigate a family with 
a rare skeletal disease with short stature is crucial for a 
successful diagnosis (Fig. 3).
In last decades, the field of clinical genetics has greatly 
evolved thanks to the development of novel sequencing 
technologies and the advances in molecular biology. 
Before the MPS era, novel genes underlying monogenic 
conditions were mapped by positional cloning and linkage 
analysis. These methods, which allowed the identification 
of large regions to be prioritized by Sanger sequencing, 
were not only time consuming but they also required 
large multi-case pedigrees. Nowadays, Sanger sequencing 
is only used to sequence one or a couple of candidate 
genes/exons when a disease-gene correlation is suspected. 
Since the majority of skeletal diseases is characterized 
by genetic heterogeneity, methods that allow to screen 
several loci at the same time are often required (Fig. 
3). Among the different MPS methods, gene panels 
are designed for capturing and sequencing a certain 
number of candidate genes. Running a gene panel has 
become a faster and less expensive alternative to Sanger 
sequencing (66). 
Alternatively, when the investigated phenotype 
overlaps with more than one condition and/or a long list 
of genes needs to be screened, exome sequencing (ES) is 
a more cost-effective option. ES gives the possibility not 
only to screen for variants in known disease-causing genes 
but also to search for variants in the rest of the protein-
coding genes. 
Finally, genome sequencing (GS), currently the most 
expensive method in the field, enables the sequencing of 
the entire genome. Some advantages of using GS instead 
of ES include: (1) sequencing of variants in regulatory 
regions (67) as well as deep intronic variants that could 
affect gene expression and the splicing mechanism (68), 
respectively, (2) sequencing of non-coding RNAs, such as 
miRNAs, that could regulate the expression of key genes 
in skeletogenesis, (3) more even coverage to improve the 
detection of intragenic deletions and duplications, and (4) 
possibility of detecting SVs, which are large chromosomal 
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rearrangements (>50 base pairs) (69) that could disrupt 
known disease-causing genes. Although most of the 
pathogenic variants that have so far been reported to cause 
skeletal dysplasias are small-scale variants, sometimes SVs, 
including copy number variants (CNVs), inversions and 
translocations, can give rise to skeletal diseases (70). CNVs 
can also be detected using SNP and comparative genomic 
hybridization (CGH)-arrays, two older methods that can 
pinpoint large changes in DNA copies. 
SNP-array, ES, or GS data can also be used to detect 
uniparental disomy (UPD) (71), a genetic phenomenon 
where both copies of a chromosome are inherited from 
the same parent. UPD can lead to imprinting disorders 
by disrupting the expression pattern of imprinted 
genes. For example, paternal UPD of chromosome 20 
has been reported in up to 18% of the patients with 
pseudohypoparathyroidism type 1b (PHP1b) (72) and 
maternal UPD of chromosome 7 is found in approximately 
5–10% of patients with Silver–Russell syndrome (SRS) 
(MIM 18060) (73). In addition to UPD, imprinting 
disorders are also caused by methylation defects, such 
as loss of methylation at the GNAS imprinted region in 
PHP1b (74) and loss of methylation at 11p15 in SRS (73). 
Despite the fact that nowadays large multi-case 
families are not needed to pinpoint a novel disease locus, it 
is often advantageous to perform MPS on at least a family 
trio (patient and his/her parents) in order to narrow down 
the number of rare candidate variants. 
Finally, to improve the knowledge on non-coding 
variants and to increase the diagnostic yield in skeletal 
dysplasias, a combination of ES/GS and RNA-sequencing 
might be needed. Transcriptome analysis in monogenic 
diseases does not only allow to pinpoint deep intronic 
variants and synonymous changes that affect the splicing 
Figure 3
Schematic workflow of the genetic approach to identify the disease-causing variant in a patient with a skeletal disease. After an in-depth clinical 
characterization (step 1), the phenotype of the studied patient might overlap a known condition, several conditions or be a novel/unknown phenotype; 
this will determine the genetic approach/method to be chosen (step 2). Data analysis could directly lead to a genetic diagnosis, but often further 
investigations are needed to validate a genetic finding or to pinpoint the genetic defect (step 3). ES, exome sequencing; GS, genome sequencing; SVs, 
structural variants. 
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mechanism but also to identify variants in regulatory 
regions (promoters, enhancers and UTRs) that result in 
aberrant gene expression (68). Since the transcriptome 
signatures differ in different tissues, it is crucial to perform 
the investigations on the affected tissue or to identify a 
good proxy tissue for the disease, which in the case of 
skeletal conditions would be bone and/or cartilage. 
Recently, transcriptome analysis performed on RNA 
extracted from primary skin fibroblasts of patients with 
CHH revealed differential expression of several genes 
regulating the cell cycle (75). These results suggest that if 
the investigated gene plays a pivotal role not only for the 
skeleton but also for the ectoderm, skin biopsies could be 
used as a source material to carry out RNA-sequencing. 
To summarize, it is important to choose the most 
appropriate genetic approach based on clinical evaluation 
of the patients, available resources as well as cost-
effectiveness/limitations of each method.
Validation of novel gene-disease associations
In vitro studies
Once a candidate variant in a gene that has not been 
previously linked to disease is identified, functional 
studies are needed to validate this finding. As previously 
mentioned, an important aspect to consider when 
investigating genetic findings is the source of material 
chosen/available to investigate the disease pathogenesis. 
Often, bone biopsies would be the most appropriate tissue 
and source of cells for investigating the pathogenesis 
of the disease. However, obtaining a bone biopsy is an 
invasive procedure that is not performed unless it is 
required for diagnostic purposes or the patient needs 
to undergo elective surgery. Bone biopsies are valuable 
for skeletal research since they can be used to assess 
several parameters, such as bone microarchitecture, 
mineralization, and the morphology and organization 
of the different types of bone cells (24, 76). Moreover, 
bone marrow aspirates are a source of MSCs. Although 
several protocols for osteogenic cell line differentiation 
from MSCs are available, one limitation of this method 
is related to the limited availability of these cells from 
healthy donors. 
If the studied gene is expressed in the ectoderm, most 
often skin punch biopsies obtained from patients are used 
to investigate the pathomolecular mechanisms leading 
to genetic skeletal diseases. From skin biopsies primary 
fibroblasts are derived and can be studied from different 
angles. A lot of information can be obtained for example 
by comparing cell proliferation, differentiation, and 
apoptosis as well as gene/protein expression in patients 
vs sex- and age-matched controls. However, it is always 
important to know that a defect in these cells might not 
necessarily reflect the true nature of the disease and, vice 
versa, lack of any experimental evidence in fibroblasts 
might not exclude that the pinpointed genetic finding 
has an adverse effect on bone. Despite these limitations, 
patient-derived fibroblasts are widely used in the field of 
skeletal research and have led to important discoveries. 
Moreover, dermal fibroblasts could be potentially 
reprogrammed into induced pluripotent stem cells 
(iPSCs) and re-differentiated into chondrocytes to study 
subtypes of skeletal dysplasias with short stature due 
to an intrinsic defect in the growth plate. However, 
the culture conditions allowing to differentiate 
iPSCs and MSCs into chondrocytes are not yet well 
understood (77). 
Since 2012, the CRISPR-Cas9 technology (78) 
has transformed the field of genetic engineering by 
introducing the possibility of efficiently silencing a gene 
of interest (or introducing a specific pathogenic mutation) 
in commercially available cell lines (79). While this 
approach overcomes the problem of obtaining patient-
derived osteogenic cells, the use of immortalized cell 
lines might introduce changes in the cells that might 
be incorrectly assessed as part of the phenotype induced 
by the introduced pathogenic variant/gene defect. 
Furthermore, patient-derived cells have the advantage of 
maintaining the whole genetic signature of each patient, 
thus allowing to detect the effects of potential interactions 
between a set of variants in the genome. 
In vivo models
In order to explore the systemic effects of genetic 
pathogenic variants in an organism and to investigate 
cartilage and skeletal development, animal models are 
required. Genetically engineered mice (Mus Musculus) 
have been widely used for mimicking human skeletal 
diseases since this species shares a high percentage 
of coding DNA (~85%) with humans (80) and bone 
development and the skeletal elements are highly 
conserved between these two mammalian species. Mice 
also undergo longitudinal bone growth and the growth 
plate is the structure determining cartilage production 
and bone apposition (81). Unlike in humans, the murine 
growth plate does not undergo epiphyseal fusion with 
sexual maturation (82). Concerning bone remodeling, 
it takes place in the cancellous bone, as in humans. 
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The most striking difference between mice and humans 
is that murine bone lacks osteons, the structural and 
functional units of cortical bone (81).
Since generating and handling transgenic mice is 
expensive and time consuming, zebrafish (Danio Rerio) 
has recently emerged as a model for studying rare skeletal 
diseases (83, 84, 85), primarily osteoporosis and OI (86, 
87). Approximately 71% of protein-coding genes in the 
human genome have an ortholog in zebrafish (88). Every 
week zebrafish produces hundreds of eggs, which are 
externally fertilized, thus allowing fast and easy genetic 
manipulation. Moreover, zebrafish larvae are transparent, 
and they can be stained in whole-mount to study skeletal 
development and cartilage/bone mineralization. As in 
humans, bone development in zebrafish occurs by both 
intramembranous and endochondral ossification (89) 
and several key genes playing a role in skeletogenesis 
are conserved across the two species (79, 90). Despite 
the fact that there are also dissimilarities between 
human and zebrafish skeletogenesis (e.g. in zebrafish 
bone is not vascularized and the growth plate develops 
differently), several zebrafish models mimicking human 
skeletal disease have been generated in the last decade. 
Furthermore, it has been recently shown that zebrafish 
have structures resembling the human growth plate (91). 
This finding will open the possibility to better investigate 
diseases characterized by short stature due to impaired 
growth plate in this species.
In vivo models are also largely used for drug testing 
before a candidate undergoes clinical testing in humans. 
Recently, an antibody against TGF-β was tested in two 
different mouse models of OI (92, 93) and two chemical 
chaperones were proven to improve the skeletal phenotype 
of a zebrafish model of autosomal dominant OI due to a 
missense pathogenic variant in col1a1a (94).
Significance of gene discoveries
Identifying novel pathogenic mutations and novel 
gene defects underlying skeletal diseases is important in 
order to be able to provide an accurate diagnosis to the 
patients and to offer genetic counseling and optimized 
management of the disease to the families. Moreover, 
providing the risk of having another affected child to the 
parents also influences their reproductive choices. Since 
most of the skeletal diseases still lack a pharmacological 
treatment, there is necessity for exploring novel gene 
defects to find common disease mechanisms that can 
eventually lead to the development of novel effective 
drugs. Although orthopedic surgeries will always be 
required to correct skeletal deformities and severe 
scoliosis, pharmacotherapies might help in preventing 
or ameliorating some skeletal features, in particular if 
a diagnosis is made at an early stage. Growth hormone 
therapy has been shown to help in gaining height in patients 
with short stature due to SHOX defects, but in patients 
affected by other diseases, such as spondyloepiphyseal 
dysplasia, the skeletal impairments (e.g. scoliosis) may 
even worsen with treatment (95). Therefore, it is crucial 
to distinguish between different causes for short stature 
and use personalized treatment approaches. Due to the 
mechanistic differences in disorders leading to impaired 
growth, it is important, in research settings, that novel 
genetic findings are carefully investigated using in vitro 
and in vivo models to understand the pathomolecular 
mechanisms leading to disease.
Conclusions and future perspectives
During the past 5 years, 16 novel genetic forms of SMD 
and SEMD have been characterized. These successful 
results have been achieved not only because of the 
possibility to use MPS but also because of joint efforts of 
several experts in the field aiming to identify and carefully 
delineate novel skeletal phenotypes. 
Although nowadays 92% of the thus far characterized 
skeletal conditions have a known genetic basis, it can be 
anticipated that in the near future the genetic defects 
underlying the remaining conditions will be identified. In 
addition, novel extremely rare skeletal phenotypes most 
likely continue to be characterized also in the coming 
years. A better knowledge about the non-coding genome 
and further attention on the genetic mechanisms escaping 
regular Mendelian inheritance, such as incomplete 
penetrance and somatic mosaicism, might be needed to 
solve the remaining cases of skeletal dysplasia with severe 
short stature.
Finally, the large increase in gene-disease associations 
that has characterized the last decade has lagged behind 
in in-depth characterization of the pathogenesis of these 
diseases. Additional work is, thus, required to explore 
the molecular mechanisms leading to impaired bone 
development and/or homeostasis and to pinpoint novel 
drug targets. This knowledge will eventually be applied 
to develop efficient therapeutic strategies to treat patients 
with skeletal diseases.
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